For instance, Li et al. [88] demonstrated that miR-218 directly targets leucine-rich repeat-containing G-protein-coupled receptor 4 (LGR4), an IL-6 responsive gene associated with cancer progression, and modulates phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and Wnt/β-catenin pathways in LNCaP cells treated with exogenous IL-6 (LNCaP-IL-6+). The gene discussed is AKT1; the disease is cancer.